Renal TransplantTransplant LADNCT05104242
Kidney Transplant Low-AGE Diet Study
A study testing Diet low in Advanced Glycation End-Products (AGE) in people with Renal Transplant, run by University Hospitals of Derby and Burton NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
The purpose of the present study is to test the feasibility of conducting a larger randomised controlled trial (RCT) which will investigate whether a diet low in toxins called advanced glycation end-products (AGEs) decreases skin autofluorescence (SAF; AGE accumulation in the skin) levels and improves heart and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Renal Transplant
- What is being tested?
- Diet low in Advanced Glycation End-Products (AGE)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Feb 2022to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults (>18 years) with a functioning (not on dialysis) kidney transplant.
- More than 12 months post-transplant.
- Able and willing to give informed consent.
- Skin Autofluorescence levels above the general population mean value for age.
Who cannot join
- Persons with dark skin colour (i.e. Fitzpatrick skin colour type 5-6).
- Persons with malnutrition (Subjective Global Assessment [SGA] score <5).
- Pregnancy or breast feeding or intending pregnancy.
- Active infection.
- Active rejection.
- Persons with learning difficulties.
- Prisoners.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University Hospitals of Derby and Burton NHS Foundation Trust
Derby, Derbyshire, DE22 3NE
About this study
Official title: A Feasibility Study Exploring the Impact of a Low Advanced Glycation End-product (AGE) Diet on Skin Autofluorescence (SAF) Levels in Kidney Transplant Recipients
The purpose of the present study is to test the feasibility of conducting a larger randomised controlled trial (RCT) which will investigate whether a diet low in toxins called advanced glycation end-products (AGEs) decreases skin autofluorescence (SAF; AGE accumulation in the skin) levels and improves heart and circulatory (i.e. cardiovascular) health in persons with a kidney transplant.
Read the detailed description
Kidney transplantation is the optimal treatment option for end-stage kidney disease. Cardiovascular disease is the leading cause of death in persons with kidney disease, even after receiving a kidney transplant. Advanced glycation end-products (AGEs) are compounds that form naturally in our bodies from the chemical reaction of sugars with proteins. If the concentration of AGEs becomes excessive in our bloodstream, they can cause damage to almost every tissue and organ in our bodies, which eventually may lead to an increased risk of cardiovascular death and ill health. AGEs are also found naturally in foods and the content of AGEs in foods is increased considerably by using cooking methods that require high temperatures, such as frying, roasting and grilling.
Skin autofluorescence (SAF) is a relatively new, non-invasive, validated and easy to perform technique that measures the skin accumulation of AGEs. It has been reported that kidney transplant recipients have significantly lower SAF levels when compared to persons receiving dialysis; however, these are higher than the general population.
Because of the adverse outcomes (e.g. increased risk of death) strongly associated with higher levels of SAF, several options focused on reducing the accumulation of AGEs have been proposed. One of these promising interventions is the reduction of dietary intake of AGEs. It has been suggested that cooking techniques that avoid very high temperatures such as poaching, steaming, stewing and boiling can significantly reduce the AGE content of food when compared to frying, broiling, grilling and roasting. Several studies conducted in healthy overweight and/or obese volunteers, persons with diabetes and in those with chronic kidney disease and performing peritoneal dialysis have reported that reducing dietary AGE intake is associated with a reduction in blood levels of AGEs, suggesting that a low AGE diet may also be associated with a decrease in SAF. Nevertheless, most of the evidence regarding diet modifications to reduce dietary AGE intake is of low quality and therefore further studies are required. Furthermore, this simple dietary intervention has not been previously study in the kidney transplant population. Therefore, if this proposed feasibility study is successful, we will use these findings to identify ways to design future larger research projects to improve the care of persons with a kidney transplant.
This is a feasibility study that will be conducted in two parts:
Part 1:
This will be a randomised controlled trial (RCT) aiming to recruit 40 participants with a functional kidney transplant. Participants will be assigned to either a low AGE diet (intervention group) or a standard diet for persons with a kidney transplant (control group). Participants will be followed-up for 6 months and will receive precise oral and written advice on how to follow the diets. This advice will be tailored to their needs and food preferences.Adherence to both diets will be evaluated by means of a 3-day food diary (2 weekdays and 1 weekend day) every month.
The purpose of the control group is to show what would normally happen to AGE levels in the skin and compare it with what happens to AGE levels in the skin when persons with a kidney transplant follow a low AGE diet. Therefore, this will show if the low AGE diet is really responsible of the observations.
Potential participants will be approached by the Chief Investigator (a member of the transplant team), during routine follow-up appointments. After the participants have read and understand the Participant Information Sheet (PIS), and had sufficient time (at least 24 hours) to consider their participation in this study, we will ask them to sign a consent form, which shows their willingness to take part. We will then collect information from their medical records or direct interview about their age, ethnicity, medical conditions, educational level, employment and smoking status, medication, alcohol history, and information about their transplant and kidney disease.
During the first study assessment, we will:
- Measure the accumulation of toxins (AGEs) in the skin using a safe, quick (less than five minutes) and painless technique called skin autofluorescence. This involves placing the forearm on a piece of equipment that shines a light on the skin and measures the amount of light that is reflected back.
- Take routine blood samples and blood pressure.
- Ask participants to complete a quality of life questionnaire (EQ-5D-5L), a 3-day food diary (2 weekdays and 1 weekend day) to assess energy, fat and protein intake and a validated food frequency questionnaire to evaluate dietary AGE intake.
- Assess nutritional status using the validated 7-point scale Subjective Global Assessment.
- Measure weight, height, mid-arm circumference, triceps skinfold thickness, handgrip strength and aortic pulse wave velocity (a measure of cardiovascular health).
These same procedures and measurements will be conducted at 3 and 6 months of follow-up.
Part 2:
Once the RCT (Part 1) has finished, 10 participants from the intervention group and 5 from the control group (ensuring as far as possible that the sample includes a diverse representation of the study population), will be invited to take part in interviews asking questions about the acceptability and tolerability of the intervention (low AGE diet), as well as feedback about the study process.
Potential participants will be given or sent an invitation letter and PIS, have the study explained to them and consented separately. The interview will take place at a time and location convenient to the participants and will take about 60 minutes.
- Conditions
- Renal Transplant
- Being tested
- Diet low in Advanced Glycation End-Products (AGE)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diet low in Advanced Glycation End-Products (AGE)Other
The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
| Study group | Role | What they receive |
|---|---|---|
| Standard diet - Control group | No intervention | The standard diet will include energy intake of 30-35 kcal/kg of ideal body weight (IBW)/day and protein intake of 0.75 g/kg of IBW/day for females and 0.84 g/kg of IBW/day for males |
| Low AGE diet - Intervention group | Experimental | The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as "allowed," "moderate intake," or "occasional." The goal will be to reduce dietary AGE intake to less than 8000 kU/day. Receives: Other: Diet low in Advanced Glycation End-Products (AGE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Autofluorescence (SAF) Levels at 6 Months
Tissue accumulation of advanced glycation end-products was assessed by measuring skin autofluorescence (SAF) using a validated Autofluorescence Reader. SAF is calculated as the ratio between emission and excitation and is expressed as arbitrary units (AU). Three measurements were conducted and the average value of these was used for statistical analysis. SAF reference value for the age group of 50-60 years is 2.1±0.4 AU
Measured: 6 months
Secondary outcomes (3)
Participant Adherence to Diets
Adherence to the low AGE diet (achieving dietary AGE intake <8000 kilounits [kU]/day) and the standard diet for persons with a kidney transplant was evaluated by means of a 3-day food diary (2 weekdays and 1 weekend day) every month (i.e., assessed from 1-6 months but only adherence at 6 months was reported).
Measured: 6 months
Skin Autofluorescence (SAF) Trend.
SAF was measured at baseline, 3 and 6 months. The rate of change of SAF among these 3 time points (i.e., SAF trend) was then calculated by fitting a regression line using the SLOPE function in Microsoft Excel 2016, where the y-axis represented SAF values and the x-axis represented time points.
Measured: 0, 3 and 6 months
Dietary AGE Intake at 6 Months
A validated food frequency questionnaire was used to quantify the content of AGEs in foods.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2021
- Study start4 Feb 2022
- Primary completion8 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Renal TransplantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- British Renal Society, Kidney Care UK
- Responsible party
- Sponsor
- Investigators
- Catherine Johnson, Principal investigator, University Hospitals of Derby and Burton NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05104242
- Sponsor's protocol ID
- UHDB/2020/018
- Acronym
- Transplant LAD
- Status last verified
- Dec 2024
- First submitted
- 21 Oct 2021
- Last updated
- 6 Dec 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Feasibility Study Exploring the Impact of a Low Advanced Glycation End-product (AGE) Diet on Skin Autofluorescence (SAF) Levels in Kidney Transplant Recipients
- ClinicalTrials.gov ID
- NCT05104242
- Acronym / sponsor ID
- Transplant LAD / UHDB/2020/018
- Conditions
- Renal Transplant
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- University Hospitals of Derby and Burton NHS Foundation TrustUniversity, hospital or other
- Collaborators
- British Renal Society, Kidney Care UK
- Study start
- 4 Feb 2022 (actual)
- Primary completion
- 8 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 2 Nov 2021 (actual)
- Results
- Posted 6 Dec 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the present study is to test the feasibility of conducting a larger randomised controlled trial (RCT) which will investigate whether a diet low in toxins called advanced glycation end-products (AGEs) decreases skin autofluorescence (SAF; AGE accumulation in the skin) levels and improves heart and circulatory (i.e. cardiovascular) health in persons with a kidney transplant.
Detailed description
Kidney transplantation is the optimal treatment option for end-stage kidney disease. Cardiovascular disease is the leading cause of death in persons with kidney disease, even after receiving a kidney transplant. Advanced glycation end-products (AGEs) are compounds that form naturally in our bodies from the chemical reaction of sugars with proteins. If the concentration of AGEs becomes excessive in our bloodstream, they can cause damage to almost every tissue and organ in our bodies, which eventually may lead to an increased risk of cardiovascular death and ill health. AGEs are also found naturally in foods and the content of AGEs in foods is increased considerably by using cooking methods that require high temperatures, such as frying, roasting and grilling.
Skin autofluorescence (SAF) is a relatively new, non-invasive, validated and easy to perform technique that measures the skin accumulation of AGEs. It has been reported that kidney transplant recipients have significantly lower SAF levels when compared to persons receiving dialysis; however, these are higher than the general population.
Because of the adverse outcomes (e.g. increased risk of death) strongly associated with higher levels of SAF, several options focused on reducing the accumulation of AGEs have been proposed. One of these promising interventions is the reduction of dietary intake of AGEs. It has been suggested that cooking techniques that avoid very high temperatures such as poaching, steaming, stewing and boiling can significantly reduce the AGE content of food when compared to frying, broiling, grilling and roasting. Several studies conducted in healthy overweight and/or obese volunteers, persons with diabetes and in those with chronic kidney disease and performing peritoneal dialysis have reported that reducing dietary AGE intake is associated with a reduction in blood levels of AGEs, suggesting that a low AGE diet may also be associated with a decrease in SAF. Nevertheless, most of the evidence regarding diet modifications to reduce dietary AGE intake is of low quality and therefore further studies are required. Furthermore, this simple dietary intervention has not been previously study in the kidney transplant population. Therefore, if this proposed feasibility study is successful, we will use these findings to identify ways to design future larger research projects to improve the care of persons with a kidney transplant.
This is a feasibility study that will be conducted in two parts:
Part 1:
This will be a randomised controlled trial (RCT) aiming to recruit 40 participants with a functional kidney transplant. Participants will be assigned to either a low AGE diet (intervention group) or a standard diet for persons with a kidney transplant (control group). Participants will be followed-up for 6 months and will receive precise oral and written advice on how to follow the diets. This advice will be tailored to their needs and food preferences.Adherence to both diets will be evaluated by means of a 3-day food diary (2 weekdays and 1 weekend day) every month.
The purpose of the control group is to show what would normally happen to AGE levels in the skin and compare it with what happens to AGE levels in the skin when persons with a kidney transplant follow a low AGE diet. Therefore, this will show if the low AGE diet is really responsible of the observations.
Potential participants will be approached by the Chief Investigator (a member of the transplant team), during routine follow-up appointments. After the participants have read and understand the Participant Information Sheet (PIS), and had sufficient time (at least 24 hours) to consider their participation in this study, we will ask them to sign a consent form, which shows their willingness to take part. We will then collect information from their medical records or direct interview about their age, ethnicity, medical conditions, educational level, employment and smoking status, medication, alcohol history, and information about their transplant and kidney disease.
During the first study assessment, we will:
- Measure the accumulation of toxins (AGEs) in the skin using a safe, quick (less than five minutes) and painless technique called skin autofluorescence. This involves placing the forearm on a piece of equipment that shines a light on the skin and measures the amount of light that is reflected back.
- Take routine blood samples and blood pressure.
- Ask participants to complete a quality of life questionnaire (EQ-5D-5L), a 3-day food diary (2 weekdays and 1 weekend day) to assess energy, fat and protein intake and a validated food frequency questionnaire to evaluate dietary AGE intake.
- Assess nutritional status using the validated 7-point scale Subjective Global Assessment.
- Measure weight, height, mid-arm circumference, triceps skinfold thickness, handgrip strength and aortic pulse wave velocity (a measure of cardiovascular health).
These same procedures and measurements will be conducted at 3 and 6 months of follow-up.
Part 2:
Once the RCT (Part 1) has finished, 10 participants from the intervention group and 5 from the control group (ensuring as far as possible that the sample includes a diverse representation of the study population), will be invited to take part in interviews asking questions about the acceptability and tolerability of the intervention (low AGE diet), as well as feedback about the study process.
Potential participants will be given or sent an invitation letter and PIS, have the study explained to them and consented separately. The interview will take place at a time and location convenient to the participants and will take about 60 minutes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard diet - Control group | No intervention | –The standard diet will include energy intake of 30-35 kcal/kg of ideal body weight (IBW)/day and protein intake of 0.75 g/kg of IBW/day for females and 0.84 g/kg of IBW/day for males |
| Low AGE diet - Intervention group | Experimental | Other: Diet low in Advanced Glycation End-Products (AGE)The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as "allowed," "moderate intake," or "occasional." The goal will be to reduce dietary AGE intake to less than 8000 kU/day. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults (>18 years) with a functioning (not on dialysis) kidney transplant.
- More than 12 months post-transplant.
- Able and willing to give informed consent.
- Skin Autofluorescence levels above the general population mean value for age.
Key exclusion criteria (7 listed)
- Persons with dark skin colour (i.e. Fitzpatrick skin colour type 5-6).
- Persons with malnutrition (Subjective Global Assessment [SGA] score <5).
- Pregnancy or breast feeding or intending pregnancy.
- Active infection.
- Active rejection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diet low in Advanced Glycation End-Products (AGE)The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences | Other | Low AGE diet - Intervention group |
Primary outcome
Skin Autofluorescence (SAF) Levels at 6 Months
Time frame: 6 months
Tissue accumulation of advanced glycation end-products was assessed by measuring skin autofluorescence (SAF) using a validated Autofluorescence Reader. SAF is calculated as the ratio between emission and excitation and is expressed as arbitrary units (AU). Three measurements were conducted and the average value of these was used for statistical analysis. SAF reference value for the age group of 50-60 years is 2.1±0.4 AU
3 secondary outcomes
Participant Adherence to Diets
Time frame: 6 months
Skin Autofluorescence (SAF) Trend.
Time frame: 0, 3 and 6 months
Dietary AGE Intake at 6 Months
Time frame: 6 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Renal Transplant
RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Cytomegalovirus Prophylaxis
Not yet recruiting
Bioimpedance and Multiparametric Ultrasound-Guided Fluid Management After Kidney Transplantation
Kidney Transplantation, Delayed Graft Function
Active, not recruiting
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Transplant;Failure,Kidney, Transplant; Failure, Liver
RecruitingPhase 2
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Microvascular Inflammation
Active, not recruitingPhase 2
Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial
Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Catherine Johnson principal investigator
University Hospitals of Derby and Burton NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diet low in Advanced Glycation End-Products (AGE) in people with Renal Transplant, run by University Hospitals of Derby and Burton NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Dec 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Autofluorescence (SAF) Levels at 6 Months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2024.